论文部分内容阅读
目的分析探讨瑞替普酶联合还原型谷胱甘肽治疗急性ST段抬高型心肌梗死(STEMI)的临床疗效。方法 99例急性ST段抬高型心肌梗死患者,采用随机数字表法分为观察组(49例)和对照组(50例)。对照组患者采用瑞替普酶治疗,观察组患者采用瑞替普酶联合还原型谷胱甘肽治疗。比较两组患者的血管再通情况、临床疗效、不良反应发生情况。结果观察组血管再通率83.67%及总有效率91.84%均高于对照组66.00%、76.00%,差异均有统计学意义(χ~2=4.095、4.581,P<0.05)。观察组不良反应发生率22.45%低于对照组42.00%,差异有统计学意义(χ~2=4.324,P<0.05)。结论相对于单纯瑞替普酶治疗,联合还原型谷胱甘肽治疗急性ST段抬高型心肌梗死效果更为显著,且安全性高。
Objective To investigate the clinical efficacy of reteplase combined with reduced glutathione in the treatment of acute ST-segment elevation myocardial infarction (STEMI). Methods Ninety-nine patients with acute ST-segment elevation myocardial infarction were divided into observation group (49 cases) and control group (50 cases) by random number table. Patients in the control group were treated with reteplase, and patients in the observation group were treated with reteplase plus reduced glutathione. Compare the two groups of patients recanalization, clinical efficacy, adverse reactions occurred. Results The rate of vascular recanalization in observation group was 83.67% and the total effective rate was 91.84%, which was significantly higher than that in control group (66.00% and 76.00%, respectively) (χ ~ 2 = 4.095,4.581, P <0.05). The incidence of adverse reactions in observation group was lower than 22.45% in control group (42.00%), the difference was statistically significant (χ ~ 2 = 4.324, P <0.05). Conclusion Compared with the simple reteplase treatment, combined with reduced glutathione treatment of acute ST-elevation myocardial infarction effect is more significant and safe.